Italy's National Health Institute (ISS) has recommended that pregnant women should get COVID-19 vaccines after the first three months of their pregnancy, Reuters news agency reported on Friday.
The Italian health authority stated that it was advising women to receive two mRNA-based shots in the second and third trimesters of pregnancy.
According to the ISS, its decision was due to growing evidence on the safety of vaccines during pregnancies for both the foetus and the mother.
Women who are breastfeeding can safely get vaccinated, ISS adding, saying that infants can safely absorb antibodies via milk.
Italy is currently administering two vaccines based on messenger RNA (mRNA) technology, one made by BioNTech (Nasdaq:BNTX) in partnership with Pfizer (NYSE:PFE), and a second from Moderna Inc (Nasdaq:MRNA).
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio
GSK and IQVIA expand vaccine track with local data to drive targeted public health action